US 12,083,136 B2
Combination of BCL-2/BCL-XL inhibitors and chemotherapeutic agent and use thereof
Dajun Yang, Suzhou (CN); Yifan Zhai, Suzhou (CN); Guangfeng Wang, Suzhou (CN); Douglas Dong Fang, Suzhou (CN); Jing Deng, Suzhou (CN); Miaozhen Qiu, Suzhou (CN); and Lin Zhang, Suzhou (CN)
Assigned to ASCENTAGE PHARMA (SUZHOU) CO., LTD, Suzhou (CN)
Appl. No. 16/630,855
Filed by ASCENTAGE PHARMA (SUZHOU) CO., LTD., Suzhou (CN)
PCT Filed Jul. 31, 2019, PCT No. PCT/CN2019/098576
§ 371(c)(1), (2) Date Jan. 14, 2020,
PCT Pub. No. WO2020/024976, PCT Pub. Date Feb. 6, 2020.
Claims priority of application No. 201810914839.4 (CN), filed on Jul. 31, 2018; application No. PCT/CN2019/074862 (WO), filed on Feb. 12, 2019; application No. 201910598720.5 (CN), filed on Jul. 4, 2019; and application No. 201910662265.0 (CN), filed on Jul. 22, 2019.
Prior Publication US 2021/0060039 A1, Mar. 4, 2021
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/675 (2006.01); A61K 9/00 (2006.01); A61K 31/337 (2006.01); A61K 31/4045 (2006.01); A61K 31/4745 (2006.01); A61K 31/496 (2006.01); A61K 31/513 (2006.01); A61K 33/243 (2019.01); A61P 35/00 (2006.01); A61P 35/04 (2006.01)
CPC A61K 31/675 (2013.01) [A61K 31/337 (2013.01); A61K 31/4045 (2013.01); A61K 31/4745 (2013.01); A61K 31/496 (2013.01); A61K 31/513 (2013.01); A61K 33/243 (2019.01); A61P 35/00 (2018.01); A61P 35/04 (2018.01)] 4 Claims
 
1. A method of treating cancer comprising administering to a subject in need thereof a therapeutically effective amount of a Bcl-2/Bcl-xL inhibitor and a therapeutically effective amount of a chemotherapeutic agent, wherein the Bcl-2/Bcl-xL inhibitor is

OG Complex Work Unit Chemistry
or a pharmaceutically acceptable salt thereof,
wherein the chemotherapeutic agent is docetaxel or paclitaxel, and
wherein the cancer is small cell lung cancer.